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Abstract 
Diabetes mellitus (DM) is a detrimental disease that afflicts approximately 23.6 million 
Americans and costs $176 billion dollars annually in direct medical expenses (American 
Diabetes Association [ADA], 2015).  Approximately 208,000 children and adolescents with 
diabetes are under the age of 20 years (ADA, 105; CDC, 2014).  Currently, the standard of 
medical practice in school-aged children and adolescents with type 1 diabetes is to administer 
insulin after the child or teen has eaten.  The most current evidence has demonstrated a decrease 
hemoglobin A1C (HbA1c) and preference for pre-prandial insulin administration (Cobry et al., 
2010; Danne et al., 2003; DePalma et al., 2011; Enander et al., 2012; Luijf et al., 2010; 
Scaramuzza et al., 2010).  This Doctor of Nursing Practice (DNP) project delivered an 
educational program for parents of school age children and adolescents with type 1 diabetes and 
instituted pre-prandial insulin administration as the standard of care in an outpatient pediatric 
endocrine clinic.  Education was delivered in both verbal and written formats.  Data collection 
included weekly blood glucose reports and HbA1c at initial and follow-up sessions.  Descriptive 
statistics were utilized to analyze the data. No post intervention data was able to be collected due 
to participant drop out. Future directions to promote this practice change are discussed. 
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Background and Significance 
 According to the United States (U.S.) Department of Health and Human Services (2014), 
diabetes mellitus (DM) affects approximately 23.6 million people and is the seventh leading 
cause of death in the U.S.  The total cost for direct medical expenses due to DM in 2012 was 176 
billion dollars (ADA, 2015).  Data from the Center of Disease Control and Prevention (CDC) 
and the American Diabetes Association (ADA) in 2008-2009, estimated 208,000 individuals 
with diabetes are under the age of 20 years, and roughly 18,436 children are diagnosed with type 
1 DM (ADA, 2015; CDC, 2014).  The prevalence of diabetes is higher in Hispanic, African 
American, Asian, Pacific Islander, and American Indians ethnicities (CDC, 2015).  
Type 1 DM is a condition resulting from a defective or failure of pancreatic beta cells to 
secrete insulin (ADA, 2016).  Without insulin, glucose cannot enter the cells to be turned into 
energy and this impairs the body’s ability to metabolize carbohydrate, protein, and fat correctly 
which results in hyperglycemia or high blood glucose (Burns et al., 2013).  Prolonged 
uncontrolled blood glucose can have detrimental health sequelae in adulthood such as 
hypertension, amputations, blindness, stroke, and renal disease (ADA, 2014; NDEP, 20014).   
Currently, the standard of care for insulin administration is to dose insulin pre-prandial. 
However, this type of administration can be difficult in young children due to their unpredictable 
appetite and oral intake.  This creates a barrier in preventing adequate control of blood glucose 
(BG) and subsequently hemoglobin A1c (HbA1c) levels. 
Purpose and Rationale  
 The goal of diabetes management is to decrease health sequelae and improve quality of 
life.  One way to achieve these goals is through improved management of BG and HbA1c.  
Therefore, the purpose of this Doctor of Nursing Practice (DNP) project is to implement an 
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insulin administration practice change which is demonstrating efficacy in the most recent 
scientific literature.  According to the most current evidence, school-aged children and 
adolescents with Type 1 DM will benefit from changing insulin administration from a post-
prandial insulin administration to a pre-prandial insulin administration.  The evidence suggests 
that this timing of insulin administration contributes to better current and future health.  
Internal Evidence 
 Horizon View Medical Center (HVMC) is an outpatient pediatric endocrine clinic in Las 
Vegas, Nevada. At this clinic, it has been noted that approximately 50% of the daily pediatric 
patient visits are related to DM.  Currently, all of the children who are insulin dependent are 
administering insulin at the post-prandial time point which is the opposite practice from what this 
author observed when working as a Registered Nurse on an adult medical-surgical floor.  When 
the healthcare providers at the clinic were questioned about this practice, the reply was simply 
because some children do not know how much carbohydrate they will consume at each meal in 
order to correctly compensate pre-prandial insulin administration.     
Problem Statement  
 It is imperative to monitor BG and HbA1c to better manage DM (Chase, 2011; Valent et 
al., 2010; World Health Organization, 2011).  In a cohort study by Samahy, Elbarbary, and 
Elmorsi (2015), poor glycemic control was detrimental and caused acute complications such as 
diabetic ketoacidosis (DKA) or severe hypoglycemia.  In addition, the following chronic 
conditions in pediatric patients were the result of uncontrolled BG: neuropathy 6.3%, retinopathy 
1.8%, and microalbuminuria 6.8% (Samahy et al., 2015).   
 Timely insulin administration is both necessary and imperative to adequately control 
post-prandial BG, episodes of nocturnal hypoglycemia, and HbA1c (Cobry et al., 2010; Danne et 
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al., 2003; Scaramuzza et al., 2010).  According to Scaramuzza et al. (2010), pre-prandial insulin 
administration, either 15 minutes or immediately prior to a meal, was more effective than post-
prandial administration in keeping BG stable and closer to therapeutic levels.  A randomized 
control study by, Enander, Gundevall, Stromgren, Chaplin, and Hanas (2012), showed a 
significant reduction by 0.5% in HbA1c in participants who administered pre-prandial insulin 
based on counting their carbohydrate consumption.  Another randomized study on pre- versus 
post insulin administration by Ratner, Wynne, Nakhle, Brusco, Vlajnic, and Rendel (2011) did 
not find a significant difference in HbA1c level. However, they did find fewer symptoms and 
episodes of nocturnal hypoglycemia.  It appears that there is a growing body of evidence 
supporting pre-prandial insulin administration to better control BG and HbA1c.  
 The emerging evidence of the effectiveness of pre-prandial insulin administration has led 
to the clinically relevant PICOT question: In diabetic school-aged children (P), how does pre-
prandial insulin administration (I), versus standard of care (C), affect HbA1c (O) over three 
months (T).  
Search Strategy 
 In order to answer the aforementioned PICOT question, a comprehensive literature search 
was conducted via the following databases: Cochrane Library, PubMed, and the Cumulative 
Index to Nursing and Allied Health Literature (CINAHL). A combination of the following 
keywords were used within each database: school-aged children(s), pediatric(s), adolescent(s), 
children(s), youth(s), diabetes, diabetic(s), pre-prandial, before meal(s), post-prandial, after 
meal(s), blood sugar, blood glucose, HbA1c, HgA1c, A1c, insulin administration, insulin 
injection, meal dosing, meal time injection, and timing of meal injection/administration.  
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Boolean connectors AND, OR, IN, and FOR were used in various places within the search as 
well. In addition, an ancestry and cross reference search was identified through relevant articles. 
PubMed 
 Initially, the search in PubMed yielded 148 articles.  When searched using "timing of 
insulin administration AND children AND blood sugar", the search yielded 30 articles.  In 
limiting publication dates to the last five years and the human species, nine articles were found 
but only two were applicable and retained for further review.   
CINAHL 
 The search in CINAHL resulted in 28 articles with the following terms: timing of insulin 
administration AND children AND blood sugar.  The search was refined to include the English 
language, within the last five years, all child, and publications for pediatric diabetes which 
resulted in 10 studies.  Boolean phrases used were: Blood glucose/AND OR Diabetes Mellitus.  
The search was further broken down into major headings using BG yielding a final result of three 
articles.  Two studies were retained for further evaluation.  
Cochrane Library 
 The search for pre-prandial insulin administration in the Cochrane Library yielded 10 
studies.  Using the MeSH term hemoglobin A, and Glycosylated (HbA1), the search yielded 20 
Cochrane reviews.  Other MeSH terms used included: Diabetes Mellitus and BG self-monitoring.  
The search phrase “pre-prandial insulin injection” and limiting the search to articles from 2010 to 
2015 yielded 12 articles.  Of the 12 articles, four were included for further review.  
 After this exhaustive literature search, eleven studies were chosen for further review and 
critically appraised in order to place the salient points in an evaluation table.  The studies 
consisted of five randomized cross over studies, one non-randomized cross over study, one 
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randomized controlled trial, one non-randomized controlled trial, two pilot studies, and one 
systematic literature review.  Articles pertaining to the adult population and older than five years 
were included due to limited number of studies performed on the subject and conducted with the 
pediatric population.  However, these studies had significant findings supporting pre-prandial 
insulin administration.  Some studies were excluded because it did not pertain to insulin timing 
comparison.   
Critical Appraisal and Synthesis of Evidence 
 Overall, the studies chosen for further review were strong, good quality studies consisting 
of one level I, seven level II, and three level III studies using Fineout-Overholt & Melnyk 
(2006), rapid appraisal for RCT's.  Seven studies were performed within the last five years and 
four were more dated due to limited studies on the subject matter in the pediatric population.  
The majority of the studies were randomized crossover studies. The remainder were non-
randomized cross over, crossover, or pilot studies.  
The eleven studies exhibited a moderate to strong degree of homogeneity in diagnosis, 
insulin dependence, and major variables as shown in the synthesis Table 2 (Appendix F). 
However, heterogeneity was observed in the demographics because studies on adults were 
included (Appendix E).  The population age ranges from two to 82 years of age.  Although the 
population age ranged widely across the lifespan, nine of the studies included participants within 
the targeted age group (Corby et al., 2010; Danne et al., 2003; Danne et al., 2007; DePalma et al., 
2011; Enander et al., 2012; Fullerton et al., 2014; Luijf et al., 2010; Scaramuzza et al., 2010; 
Schernthaner et al., 2004). Four studies were conducted in a hospital setting and six were in an 
outpatient setting.  Although eight studies were conducted outside the U.S., the findings can 
likely be generalized as they focused on the same diagnosis and utilized similar inclusion and 
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exclusion criteria.  There was strong homogeneity in the variables of interest amongst the eleven 
studies.  Nine of eleven studies had post-prandial BG as the independent variable and timing of 
insulin administration as the dependent variable.  Seven out of eleven studies measured post-
prandial BG differences between the timing of insulin administration.   
The majority of the studies utilized the following statistical analysis: level of significance 
(p), ANOVA, and t-test.  Other statistical analyses that were used in less than three studies 
include: 95% confidence interval (CI), trapezoidal method for area under the curve (AUC), 
standard deviations (SD), Pearson's correlation coefficient, degree of power, Fisher's exact test, 
7-point blood glucose profile, and Wilcoxon's test.  The statistical analysis aids the reader to 
extrapolate significant results in order to take action (Kellar and Kelvin, 2013).  The brand of 
glucose monitor used were not consistent in all eleven studies, however, quality controls were 
performed in most studies to ensure accuracy of the monitors utilized. The measurement tools 
used to measure BG was not consistent throughout the eleven studies.  Six out of eleven studies 
received funding from various drug and medical equipment companies raising the suspicion for 
bias, however all authors denied any potential bias.   
Conclusion of Evidence 
 Overall, the eleven studies had a similar conclusion: pre-prandial insulin administration is 
the preferred practice over post-prandial insulin administration.  Improved post-prandial BG, less 
glucose excursions, greater patient satisfaction, and decreasing BMI also were found as a result 
of pre-prandial insulin administration.  Therefore, this proposed Doctor of Nursing Practice 
(DNP) project plans to develop and deliver an educational program for parents of type 1 school-
aged and adolescents with diabetes and institute pre-prandial insulin administration as the 
standard of care in an outpatient pediatric endocrine clinic.   
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Chapter 2 
   The purpose of this DNP project is to critically analyze the literature for supporting 
evidence to guide nursing practice in order to promote health.  However, translating evidence 
into practice is an arduous task.  The use of theory and models were utilized to assist and guide 
this DNP project.   
John Hopkins Evidence-Based Model  
The John Hopkins Evidence Based Practice (JHNEBP) model was chosen to guide this 
DNP practice change project. The model involves three major process: practice question, 
evidence, and translation (Newhouse et al., 2007).  The practice question is the evidence-based 
practice (EBP) question and assigning roles.  The second process involves identifying internal 
and external evidence, appraising the evidence, and developing recommendations based on 
strength of evidence (Newhouse et al., 2007).  The final process is translation, which involves 
determining feasibility, creating an action plan, implementing change, evaluating outcomes, 
identifying next steps, and communicating findings (Newhouse et al., 2007).  The JHNEBP 
model is fitting to guide the proposed DNP project which will lead to a practice change because 
it recommends in-depth investigation of evidence, risks, harms, applicability, and outcomes.   
In following each step of the process, the model clearly gives guidance to find solutions 
to clinical problems in need of a practice change.  Step 1 of the model was depicted through the 
identification of the PICOT question.  Step 2 involves gathering evidence both in practice and 
from the literature to support or dismiss the practice change (i.e., pre-prandial insulin 
administration).  In appraising the evidence, strength and applicability of a study can be 
identified and used to determine the reliability and validity of the results.  Lastly, the model 
suggest that a plan of action be implemented in practice that is based on the evidence which 
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supports pre-prandial insulin administration in pediatric patients.  The goal is to educate parents 
and children and eventually mainstream pre-prandial insulin administration in school-aged 
children in an outpatient pediatric endocrine clinic.   
  Imogene King’s theory of goal attainment also was used to guide this project.  This mid-
range theory incorporates the following concepts: stress, personal space, self, perception, time, 
growth and development, communication, interaction, transaction, and role (Parker and Smith, 
2010).  The transaction process model is a universal model that can be applied to just about any 
scenario involving at least two persons (Parker and Smith, 2010).  It is through this interaction 
that goals are set and obtained.  Using the transaction process model, a goal was set with patient 
and parent. The dyad received education regarding pre-prandial insulin administration and 
agreed to change their practice of administering insulin after eating.  The goal is to improve BG 
and HbA1c in children with type 1 diabetics through pre-prandial insulin administration.  Closer 
blood glucose control may prevent detrimental future sequelae such as neuropathy, blindness, 
and amputations.   
Methods 
Ethical Approval  
 Online training Collaborative Institutional Training Initiative (CITI) was completed prior 
to beginning the DNP project.  Modules were completed for informed consent, the Health 
Insurance Portability and Accountability Act (HIPAA), basic IRB regulation and review process, 
vulnerable subjects, conflict of interest in research involving human subjects, assessing risks, 
privacy and confidentiality, and data management.  A certificate of completion was obtained 
after completing the modules and exam.  In addition, approval from Arizona State University’s 
IRB was granted on January 3, 2016 (Appendix G). 
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Participants and Setting   
 Horizon View Medical Center’s (HVMC) outpatient pediatric endocrinology office was 
chosen for the location for this DNP project due to access of the targeted population. A letter of 
support can be viewed in Appendix H.  Recruitment and data collection were performed during 
routine office visits.  All parents with children who have type 1 diabetes were given an 
explanatory introduction letter from the medical assistant at check-in (Appendix J).  The 
inclusion criteria to participate in the project included: children ages six to 18 years, diagnosed 
with type 1 diabetes, English speaking, diagnosed for three or more years, have a hemoglobin 
A1c (HbA1c) of at least eight percent since last visit, and who are medically stable on their 
current insulin regimen.   
Procedure 
 If parents were interested in participating and met the inclusion criteria, Ngoc Quyen Bui, 
Doctor of Nursing Practice (DNP) student answered questions or concerns that the parent and 
child may have.  Informed consent, assent, and pre-survey questionnaires were completed during 
the initial visit by parents and children.  The parent created a four digit identification (ID) 
number with the last four digits of their phone number to ensure confidentiality (Appendix K).  
Information regarding weekly blood glucose reports and blood results for blood glucose and 
HbA1c were obtained via electronic medical records.  In addition, teaching was done in both 
verbal and a written format during the initial visit (Appendix L).  Verbal teaching regarding 
insulin injection sites, rotation of sites, rotation techniques, when to change the insulin cartridge, 
and sick days were reinforced with parent and child during the initial visit. Common injection 
sites were: abdominal region, lower back side, thigh, and back of arms.  The W, M, or circle 
method can be used for site rotation to prevent scar tissue buildup. Sites should be rotated every 
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3 days along with the insulin cartridge change. Parents were reinforced to substitute 
carbohydrates with sugary drinks or soft foods when the child cannot tolerate solids during a 
gastrointestinal or other minor acute illness. The parents also were taught to check blood glucose 
more frequently (every 2-3 hours) and urine for ketones when the child was ill. The teaching 
handout contained information on the sliding scale with different BG levels and time for 
administration.  Parents were instructed to always carry glucose tablets and intramuscular 
glucagon for hypoglycemic episodes.  For medical emergency, parents were advised to call 9-1-1 
then notify the endocrinology’s office per office routine. The pre-questionnaires contained 
questions regarding family and child demographics, general diabetes care, and current practice 
(Appendix M).  The follow-up survey was administered at the routine three month visit 
(Appendix N).   
Outcome measures 
 Content validity of pre and post surveys and educational handout was determined by Dr. 
Saad and Trisha Briones, CPNP at HVMC.  The pre and post surveys utilized a Likert type scale, 
fill in the blank, multiple choice, and open ended questions.  Data was analyzed using the 
Wilcoxson paired t-test and descriptive statistics.  
Data collection 
  The data was be stored on a password protected computer to ensure that only the 
authorized users can access the information.  Authorized users were Ms. Bui and Dr. Jacobson.  
Hard copies of the completed surveys were identified only with an identification (ID) number 
that the parent created with the last four digit of their phone number during the initial visit.  The 
de-identified data is to be stored for 6 months.  Hard copies of the surveys were shredded 
immediately upon completion of data analysis.  Ngoc Quyen Bui RN, DNP student and Diana 
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Jacobson PhD, RN, PPCNP-BC, PMHS, FAANP had full access to the data. Ms. Bui obtained 
the weekly blood glucose readings from the child’s medical record after receiving consent from 
the parents. Ms. Bui had full access to the medical records to obtain blood glucose, hemoglobin 
A1c, and weekly blood glucose report from January to May 2016. After this period, no future 
data was collected. De-identified data is planned to be presented to Horizon View Medical 
Center medical and nursing health care providers at the completion of the project.   
Budget 
 It was projected that the project would cost less than $30 to complete and the cost met 
this expectation.  The only foreseeable cost incurred was to print the pre- and post- survey 
questionnaires, consents, educational handouts, introduction letter, instructions, time, and cost 
for gasoline to travel to the endocrine clinic (Appendix I).  However, the providers at HVMC 
agreed to have the questionnaires printed in the office to help offset the cost.  There were no 
compensation offered for the participants.  In addition, the project took place during routine 
office visits with blood tests ordered and obtained at the clinic with the patient’s insurance 
covering this cost. Therefore, there were no extra costs incurred by the participants to participate 
in this DNP project.  Writing implements were available in every exam room for the participants 
to complete the questionnaires.  Estimated total time and cost for travel to the clinic was six 
hours and $30 for gasoline.  Actual cost of the project was roughly $35 dollars for printing 
services and gasoline.  
Results  
 Although 20 participants were anticipated to be recruited, this was not achieved due to 
the following circumstances: child’s HbA1c was less than 8%, the parent did not speak English, 
or the child was not ready to commit to a change in insulin administration.  A higher number of 
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participants could have been recruited if the criteria allowed for Spanish speaking dyads and a 
longer time frame was allowed for recruitment.  A total of seven participating dyads that met all 
the inclusion criteria were included in the project.   
Demographics  
The participant age ranged from eight to 17 years. There were four females and, 3 males.  
The race/ethnicity of the participants included three African Americans, three Hispanics, and one 
Hispanic/Caucasian.   
Means 
The participant’s average age was 13.9 years and average age at diagnosis was 10 years.  
The mean HbA1c recorded from the initial session was 10.33%.  Three month follow-up 
appointments were scheduled for late March 2016 or early April 2016.  A Wilcoxson paired t-
test and descriptive statistics were used to analyze the data.     
First Visit Child Survey 
 Five participants reported their current practice as only administering insulin after meals; 
one reported administering insulin after meals at school and before meals at home; and one 
participant administered insulin before meals only.  All participants were comfortable with 
insulin administration but only five knew their insulin to carbohydrate ratio.  All seven 
participants were aware of at least one of four options for treating hypoglycemia and could name 
at least two out of three potential sites for insulin administration.  
Pre-assessment Parental Survey 
 Three parents thought that pre-prandial insulin administration would help lower their 
child’s blood glucose; three did not know; and one reported only sometimes they think it does.  
Not every parent was comfortable with insulin administration.  In fact, only two reported being 
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comfortable all the time; three were comfortable most of the time; and two were somewhat 
comfortable.  However, all seven parents had knowledge of their child’s current insulin to 
carbohydrate ratio, site of insulin administration, insulin practice, and what to do on sick days.   
Post-data 
 No post-data information was available. Three patients did not keep follow-up 
appointments.  Spoke with two parents via telephone and sent post-survey via email.  Parents 
were also reminded to send blood glucose reports from the past 3 months.  Unfortunately, no 
data was received. Therefore, post intervention data analysis was unable to be completed.  
Limitations and Implications 
 Although results from data analysis is not yet available, it is expected that the results 
would mirror that of evidence synthesis from the literature.  This DNP project has the potential 
to lower BG and HbA1c for patients and help providers at HVMC to better manage type 1 DM.  
Anticipating a positive outcome, it is vital to sustain the pre-prandial insulin administration 
practice.  The biggest limitation of this project was the sample size and waiting three months for 
post data to be available.   
Discussion 
 Most of the parents I have interacted with were excited and willing to participate in a 
DNP project that could potentially help their children.  The medical assistants, healthcare 
providers, and dietician helped to identify potential participants for the project.  Without the 
support and aid of the staff, it would not have been possible to complete the project.  Ultimately, 
the goal of this DNP project was to help patients with type 1 DM gain better control of their 
condition by lowering their blood glucose and HbA1c changing their insulin administration time 
PRE-PRANDIAL INSULIN ADMINISTRATION 16 
 
from post-prandial to pre-prandial.  In turn, this practice change also assisted providers to 
provide evidence-based care to better manage their patients’ condition.  
Chapter 3 
 Although the project got a late start and did not achieve the planned 20 participants as 
anticipated, the recruiting process went smoothly.  The project is low cost and can be easily 
replicated.  Parents were willing to participate because the project had the potential to lower 
blood glucose and HbA1c.  Current policies such as the Affordable Care Act and Children’s 
Health Insurance Program (CHIP) in Nevada helped ensure all children have access to medical 
care and financial support for medical services.  These policies were important especially for 
children with chronic diseases, such as type 1 diabetes, that require closer monitoring.      
Impact of Health Policies 
 Children of lower-income households are at a disadvantage when it comes to receiving 
the proper health care.  However, with health care initiatives like the Affordable Care Act (ACA) 
which was enacted in 2010, it is possible.  The goal of the ACA was to expand health coverage 
to all Americans, lower costs, and enhance quality of care (Medicaid, 2016).  Under the ACA, 
revisions to improve the CHIP in Nevada was established.  Some of the revisions include: year-
round open enrollment and provision for minimum mandatory benefits to prevent and treat 
health conditions (Medicaid, 2016).  This is especially important for low-income children with 
chronic conditions such as type 1 DM.  These children are insulin dependent, require frequent 
follow-ups, and laboratory blood tests.  Without coverage, these children will not have 
appropriate access to medical care and treatment.     
Leadership Role and Sustainability 
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 Prior to this DNP project, I had limited exposure to conducting a translational practice 
change project.  As a first time project director, I had a lot of fear and doubt in completing this 
project.  The topic of the project was changed several times mostly due to feasibility and site 
permission.  Once the topic and site permission was approved, the next problem to tackle was 
getting Institutional Review Board (IRB).  It was a long process but with the help of my mentor 
Dr. Diana Jacobson, IRB approval was obtained.  Sustaining participants in the project proven 
more difficult than anticipated since the protocol required the collection of post intervention data 
to be at 3 months. Three months for post intervention follow up was chosen in order to be able to 
recognize changes in HbA1C.  However, as a leader, I have learned how to overcome the 
challenges of designing and delivering a practice change intervention due to my ability to 
persevere and continue.  Lessons from this project will help with future practice change 
endeavors.   
This is a cost-effective project that will not require any additional training, guidelines, 
and no additional human labor costs.  The providers, in the future, will discuss pre-prandial 
insulin administration during scheduled visits.  Weekly blood glucose reports will continue to be 
sent via email by the parents for necessary treatment adjustments and ensure the child’s safety 
per office protocol.     
 Conclusion   
 Both providers and parents were supportive of this DNP project.  Limited resources both 
human and fiscal are needed to sustain this practice change.  During scheduled visits, providers 
can reinforce the importance of pre-prandial insulin administration.  When providers indicate 
that this practice change is evidence-based, it can help increase parental confidence and 
compliance.  In addition, there are no additional costs to incur since there are no additional extra 
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staff or materials required.  Again, the only change is the timing that insulin is instructed to be 
given.   
The eleven studies selected for critical appraisal showed improved post-prandial BG, less 
glucose excursions, greater satisfaction, and decreasing BMI as a result of pre-prandial insulin 
administration. Although larger scale research is needed, specifically in the pediatric population, 
the evidence suggests pre-prandial insulin administration should be adopted for better glycemic 
control and management of type 1 diabetes in children.  It was expected that the results of this 
DNP project would show a decrease in children’s BG and HbA1c as suggested by the literature.  
 This DNP project has taught me the value of evidence-based practice (EBP).  Learning 
about EBP in the classroom and actually seeing its potential impact in real life offers a new 
perspective in my future practice as an advanced practice nurse in pediatrics.  Personally, this 
project has motivated me not to become complacent when practicing but always question and 
search for a better solution based on evidence!   
 I hope there will be more data collected within this endocrine practice site with a greater 
number of participants but the inclusion of other outpatient endocrinology offices in Las Vegas 
or even statewide may demonstrate even future benefit.  In addition, the creation of a national 
guideline for pediatric insulin administration with specific time frames in which the pre-prandial 
insulin should be administered should be developed.   
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Appendix E 
Table 1   
 
Evaluation Table 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
Cobry (2010) 
Timing of 
meal insulin 
boluses to 
achieve 
optimal 
postprandial 
glycemic 
control in 
patients with 
type 1 diabetes 
 
L: Colorado, 
USA 
 
F: Sanofi-
Aventis 
 
C/B: NR 
PT Design: 
CO study 
 
Purpose: 
To determine 
optimal timing of 
insulin in 
relation to meal 
time to minimize 
post-prandial 
blood glucose in 
T1D.  
 
 
n = 23 
 
Demographics: 
Mean age 
(18.3) 
11 females 
12 males 
11 < 18 y/o 
12 (18-29 y/o) 
 
Setting:  
OP 
 
ATR: 0% 
 
IC: 
Diagnosed with 
T1D for 
average of 11 
years, weighs 
~52.3kg, and 
A1c ~ 7.5% 
 
EC:  
Digestive 
conditions, 
gastroparesis, 
and celiac 
disease  
LOS: 3 days  
 
DV: PP BG 
 
IV: TIA -  
 
IV1: PRE- 
20 mins PRP  
 
IV2: 
START-
immediately 
PRP 
 
IV3: POST- 
20 mins PP 
 
 
M- Freestyle 
Flash  
 
AUC  
 
GE 
 
BG max  
Fisher's exact 
test  
 
S- p < 0.05 
GE @ 60 
mins PP: 
PRE  < 
START and 
POST - p = 
0.001 
 
BG @ 120 
mins PP: 
PRE < 
START & 
POST - p = 
0.0408 
 
PRE AUC < 
START (p = 
0.0297) & 
POST (p = 
0.0463)  
 
PRE BG 
max < 
START (p = 
0.0039) & 
POST (p = 
0.0027) 
 
PRE had 
less BG > 
180 mg/dL 
vs. START ( 
LOE: III 
 
Strengths:  
Low risk 
Standardized frozen pre-packaged 
meals w/ <20g of fat and known 
carb. content 
0% ATR 
 
Limitations:  
Small sample 
 
Confidence to Act:  
Yes, the study was well designed, 
low risk, pediatric population, 
low attrition rate, and easy to 
replicate.  
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
p < 0.0001) 
& POST (p 
< 0.0001) 
Danne (2003) 
A  comparison 
of 
postprandial 
and 
preprandial 
administration 
of insulin 
Aspart in 
children and 
adolescents 
with type 1 
diabetes 
 
L: Germany 
 
F: NR 
 
C/B: NR 
PT Design: 
ROLT & CO 
 
Purpose: 
To compare 
glycemic control 
of PRP vs PP in 
children and 
adolescents with 
T1D. 
n = 76 
 
Demographics: 
Age range (6-17 
y/o) 
49%-males 
55%-<=13 y/o 
 
Setting:  
Hospital  
 
ATR: 7% 
 
IC: 
Diagnosed with 
T1D for 
average 4.4 y 
(range 1-9.4y) 
  
EC:  
TDID >= 1.8 
IU/kg, taking 
oral antidiabetic 
agents, 
unaware/recurre
nt 
hypoglycemia, 
LOS: 5 days 
 
DV: PP BG 
 
IV: TIA- 
IV1: PRE:  
Immediately 
before meal 
 
IV2: POST:  
Immediately 
after; 30 
mins max 
after 
A1c 
 
Serum 
fructosamine  
 
Satisfaction 
with DV1 vs. 
DV2  
OSNIT for 
serum 
fructosamine  
 
7-PBGP for A1c  
 
CI 95% 
 
SAS 6.12 on 
UNIX platform 
 
 
PP BG @ 
120 mins. 
DV1 < DV2 
- p = 0.016  
 
Satisfaction 
with DV1 - 
p < 0.01 
LOE:II 
 
Strengths:  
Safety was discussed 
Exclusions discussed  
Low ATR 
 
Limitations:  
Small sample 
No blinding  
No discussion of exclusion 
criteria  
Standardized meals- not 
discussed  
Statistical analysis and numerical 
data not discussed 
 
Confidence to Act:  
Yes, it is applicable to target 
population and testing methods 
are easy to replicate.   
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
significant 
concomitant 
illness pregnant, 
may become 
pregnant, 
allergy to 
product, and 
noncompliance 
with trial 
procedures  
Danne et al. 
(2007) 
Parental 
preference of 
prandial 
insulin aspart 
compared with 
preprandial 
human insulin 
a basal-bolus 
scheme with 
NPH insulin in 
a 12-wk 
crossover 
study of 
preschool 
children with 
type 1 
diabetes.  
 
PT Design: 
RCO 
 
Purpose: 
To compare S&E 
+ parental 
satisfaction of 
(IAsp + NPH 
insulin) v. (HI + 
NPH) 
n = 26 
nIAsp + NPH = 
12 
n HI + NPH = 
14 
 
Demographics: 
AA = 2.4-6.9 
y/o 
Males: 17 
Females: 9 
MA: 5 +/- 1.3 
y/o 
DD: 1.8 +/- 1 y 
A1c: 7.8 +/- 
1.1% 
 
Setting:  
OP 
 
LOS: 12 
weeks  
 
DV1: avg 
PP BG 
 
DV2:  
HbA1c 
 
DV3: 
fructosamin
e,  
 
DV4: 
satisfaction 
 
IV: TIA & 
combo  
of insulin- 
IV1: PRE 
Avg PP BG, 
A1c, 
fructosamine, 
and satisfaction 
WHO DTSQ-M- 
to assess 
treatment 
satisfaction  
 
Seven-point BG 
profiles 
NS: avg PP 
BG, A1c, or 
fructosamin
e of PRE vs. 
POST  
LOE: II 
 
Strengths:  
Randomized  
Discussion of search criteria  
 
Limitations:  
No blinding  
No homogeneity of meals and 
compliance  
Small sample sized  
No statistical method described 
Funding by Eli Lilly & Co 
 
Confidence to Act:  
Yes, the study was well designed 
and easy to replicate with 
minimal risks. 
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
L: Germany 
 
F: Novo 
Nordisk A/S, 
Denmark 
 
C/B: Yes 
ATR:  15% 
 
IC: 
Treatment with 
insulin or 
insulin analog 
>= 6M 
A1c <= 12% 
Currently 
treated with 
short, 
intermediate, or 
long acting HI 
or insulin 
analogs or self-
mixed >= 1M 
 
EC:  
Investigational 
drug within last 
month 
Hypoglycemic 
unawareness 
Allergy  
(IAsp + 
NPH ) 
 
IV2:  POST 
(HI + NPH) 
 
 
 De Palma 
(2011) 
Lowering 
postprandial 
glycemia in 
children with 
PT Design: 
PS 
 
Purpose: 
To determine 
most effective 
nScreened = 56 
n = 38 
 
Demographics: 
AA: 6-19 y/o 
n-boys = 23 
LOS: 4 days  
 
DV: PP BG  
 
IV- TIA & 
method-   
BG  
 
AUC 
Stat-graphics 
Plus 5.1 
 
Trapezoidal 
method for AUC 
 
AUC 6h BG 
PP DV3 < 
DV2 - p = 
0.01 
 
LOE: III 
 
Strengths:  
IC & EC discussed 
Feasible to replicate  
No ATR 
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
type 1 diabetes 
after Italian 
pizza 
"Marghertia"  
 
L: Italy 
 
F: None 
indicated 
 
C/B: No  
 
 
type and timing 
of bolus using 
insulin pump in 
children with 
T1D.  
n-girls = 15 
DD 8.0 +/- 4.3 
Mean BMI 21.9 
+/- 4.3 m/kg2 
ID: 0.83 +/- 
0.30 U/k/day 
A1c 7.66 +/- 
0.81% 
 
Setting:  
Hospital 
 
ATR: 0% 
 
Inclusion 
Criteria: 
DD >= 1 y, IPT 
> 6 months, 
knowledge of 
bolus calculator 
> 3 months, and 
invitational 
only.   
 
Exclusion 
Criteria: 
Eating 
disorders, 
diabetes-related 
complications, 
 
IV1- 15 
mins PRP; 
DWB  (30% 
PRE & 
70% over 
6h) 
 
IV2: 
START ; 
DWB  (30% 
PRE & 
70% over 
6h) 
 
IV3: 15 
mins PRP 
 
IV4: 
START- 
immediately 
PRP 
t-test 
 
S = p < 0.05 
 
Limitations:  
Small Sample 
 
Confidence to Act:  
Yes, the supporting evidence is 
strong and is applicable to 
pediatric population.  
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
CD, and FA.  
Enander 
(2012) 
Carbohydrate 
counting with 
a bolus 
calculator 
improves 
postprandial 
blood glucose 
levels in 
children and 
adolescents 
with type 1 
diabetes using 
insulin pumps.  
 
L: Sweden 
 
F: Fyrbodal 
Research 
Foundation, 
Skaraborg 
Research 
Foundation, 
Halland 
research 
Foundation, 
and Smith's 
Medical  
PT Design: 
RCT  
 
Purpose: 
To compare 
glycemic control 
of PRP vs PP in 
children and 
adolescents with 
T1D using carb 
counting bolus 
calculator. 
n=45 
age 13.8+/-3.4y 
(range 5-19.5) 
 
ATR: 11% 
 
Inclusion 
Criteria: 
T1D 
No previous CC 
experience 
 
EC:  
NR  
LOS: 12 
months  
 
DV: PPBG 
& HbA1c 
 
IV1: G A - 
CG 
 
IV2: G B -  
manual CC 
 
 
IV3: G C- 
CC on 
Cozmo 
pump 
A1c   
 
BG  
 
BMI 
ANOVA  
 
t-test  
 
Pearson's 
correlation 
coefficient  
 
S = p < 0.05 with 
80% power  
@ 12 
months - 
DV1 
increased 
basal insulin 
dosage/kg/2
4h - p = 
0.015 
 
DV3 < BMI 
- p = 0.029 
 
BG: DV3 < 
DV1 - p = 
0.014 
LOE: II 
 
Strengths:  
Exclusions discussed  
Randomized  
Standardized tools with same 
calibrations  
 
Limitations:  
Small sample 
No blinding  
No discussion of exclusion 
criteria  
Funding  
 
Confidence to Act:  
Yes, the study has a low ATR and 
80% power. The study is also 
easy to replicate and applicable to 
target population.  
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
 
C/B: Yes, 
from 
Medtronic, 
Roche, and 
Infucare  
Fullerton 
(2014) 
Intensive 
glucose 
control versus 
conventional 
glucose 
control for 
type 1 diabetes 
mellitus 
(Review) 
 
L:  
 
F: Federal 
Ministry of 
Education and 
Research, 
Germany 
 
C/B: No 
PT Design:  
Literature review 
of RCT’s  
 
Purpose:  
To assess effects 
of intensive vs 
conventional 
glycemic targets 
in T1D in terms 
of long-term 
complications.  
N Eligible = 
154 
N Qualitative 
Studies = 12  = 
2230 
participants  
 
N Quantitative 
= 11  
 
Demographics: 
MA for 12 
studies = 12 
years  
AR = 0-22 y/o 
 
MA for 11 
studies = 29 y/o 
AR = 26-43 y/o 
 
M A1c = 9.5% 
and 9.3% 
 
Setting:  
LOS: >= 1 
year with 1 
year follow 
up 
DV: PO, 
SO, and A1c 
 
IV-  IGC:  
* Testing 
BG >= 4 
times a day  
* Injecting 
insulin >= 3 
times a day  
* Adjusting 
insulin doses 
according to 
food intake 
and exercise 
plan 
* Making 
monthly 
visits to 
health care 
PO:  
* MC- MI, 
stroke 
* MIC- 
manifestation 
and progression 
of retinopathy, 
nephropathy, 
and ESRD 
* Severe HE 
 
SO:  
* HRQOL 
* AE- HE, KA, 
and weight gain 
* All-cause 
mortality  
* Costs  
Odds 
ratios/Risks 
ratios 
 
CI 95%  
 
Data analysis- 
Review Manager 
5.2  
 
DerSimonian 
and Laird’s 
random effects 
model  
 
Sensitivity- odds 
ratios and fixed-
effect models  
 
For rare events- 
fixed-effect 
method of Peto  
* Supports 
IGC in 
young 
people and 
at early 
stages of 
disease.  
 
* S ↓ risk 
for 
developing 
MIC in IGC 
group.  
LOE: I 
 
Strengths:  
R and high level of evidence  
Limitations:  
 
Confidence to Act:  
Yes, this review is highly reliable 
with 95% CI.   
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
 Literature 
review 
 
ATR: N/A 
 
IC: 
T1D 
Same treatment 
regimens in 
both groups 
If not same 
treatment, 
difference in 
glycemic target 
must be clearly 
identified 
  
EC:  
Unspecified 
treatment 
targets  
Non-RCT 
Study <1 year 
No relevant 
outcomes 
No separate 
analysis of 
patients with 
T1D 
Duplicate 
team 
 
IV2: CGC  
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
publication 
 
Jovanovic 
(2004)  
Efficacy 
comparison 
between 
preprandial 
and 
postprandial 
insulin aspart 
administration 
with dose 
adjustment for 
unpredictable 
meal size.  
 
L: California, 
USA 
 
F: Novo 
Nordisk 
Pharmaceutica
ls Inc and 
Sansum 
Diabetes 
Research 
Institute 
internship 
fund 
PT Design: 
RCO 
 
Purpose: 
To compare 
metabolic effects 
of preprandial vs 
postprandial 
injection of bolus 
insulin lispro. 
n = 26 
 
Demographics: 
AR: 22-82 y/o 
Mean BMI: 
26.2 kg/m2 
 
Setting:  
OP   
 
ATR: 27% 
 
IC: 
>= 18 y/o with 
T1D 
Treated with 
multiple daily 
insulin 
injections  
Able to 
calculate 
insulin-to-carb 
ratios, dose 
adjustments 
 
EC:  
Abnormal 
thyroid, renal 
LOS: 2 days 
 
DV: PP BG 
 
IV:  TIA 
 
IV1: PRE 
0-5 mins 
before start 
of meal 
 
IV2: POST  
Immediately 
after meal 
AUC 
 
Max mean (SD) 
BGC 
 
ANOVA 
 
 
S = p < 0.05 
AUC 22% 
less in DV1 
- p < 0.001 
 
Max means 
(SD): 
DV2 149.0 
(9.9) mg/dL 
vs. DV1 
102.0 (9.2) 
mg/dL- p < 
0.001 
 
both DV1 & 
DV2 had PP 
BG < 180 
mg/dL - p 
<0.001  
LOE: II 
 
Strengths:  
R, SV, and LR 
Discussion of search criteria  
 
Limitations:  
No homogeneity of meals and 
compliance  
Small sample sized  
High ATR 
Funding by Novo Nordisk 
 
Confidence to Act:  
Yes, the study was well designed, 
low risk, and well measured.  
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
 
C/B: Yes  
disease, cardiac 
ischemia, 
pregnant, and 
breastfeeding.  
 
Liberty 
(2012) 
Timing of 
insulin bolus 
in patients 
with type 1 
diabetes: 
effect on 
glucose 
control and 
variability 
using CGMS.  
 
L:  Israel 
 
F: Not 
mentioned  
 
C/B: No 
PT Design:  
BNRPS, OWB 
to BG  
 
Purpose:  
Effect of insulin 
bolus timing on 
overall daily BG 
control and 
variability. 
 
 
N = 16 
nPRE = 12 
nPOST = 12 
 
Demographics: 
>= 18 y/o 
AR: 23-71 y/o  
MA: 49.3 +/- 14 
M BMI: 27 +/- 
3.7 kg/m2 
M A1c: 6.8 +/- 
0.6% 
DD: 22.1 +/- 
11.6 y 
 
Setting:  
 OP 
 
ATR: 25% 
 
IC: 
T1D 
Multiple daily 
injections  
A1c <= 7.8% 
LOS: 3 days 
 
DV: BG 1 
& 2 hours 
PP  
 
IV- TIA- 
IV1: PRP   
 
IV2: PP  
CGM- 
MiniMed 
Medtronic  
 
A BG over 72 
hours- LBGI, 
HBGI, BGRI 
SAS 9 software 
for M 
 
Wilcoxon test for 
CG  
 
Sign test- MO 
 
MLM for MVA 
HGBI- DV2 
> DV1- p = 
0.003 
 
BGRI- DV2 
> DV1 - p = 
0.003 
LOE: II 
 
Strengths:  
R, SV, and LR 
Discussion of search criteria  
OWB  
No C/B indicated by authors  
 
 
Limitations:  
No homogeneity of meals  
Short  
High ATR  
 
Confidence to Act:  
Yes, the study is reliable and can 
be easily replicated.  
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, BGC-blood glucose concentration, BGRI-blood 
glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change 
from baseline, CG-comparison group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin infusion, DD-diabetes duration, 
DV-dependent variable, DWB-dual wave bolus, E-efficacy, EC-exclusion criteria, F-funding agency, FA-food allergy, G-group, G A-group A, G B-group B, GE-glucose excursion, HBGI-high BG 
indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
CCID  
 
EC:  
 
Luijf (2010)  
Premeal 
injection of 
rapid-acting 
insulin 
reduces 
postprandial 
glycemic 
excursions in 
type 1 
diabetes.  
 
L: Netherlands  
 
F: Medtronic 
Netherlands 
provided M's 
only  
 
C/B: No 
PT Design: 
3-way RCO 
 
Purpose: 
Effect of rapid 
acting insulin 
when given PRP 
on PP BG in 
T1D. 
 
 
n = 10 
 
Demographics: 
MA: 45.5 +/- 
12.1 y/o 
A1c 8.55 +/- 
1.50% 
DD: 23.8 +/- 
7.8 y 
Insulin therapy: 
8.5 +/- 6.1 y  
 
Setting:  
Hospital   
 
ATR: 0% 
 
IC: 
Treatment with 
CSII >= 6M 
DD: 2 y  
BMI <= 35 
kg/m2 
BG 3.5-7.8 
mmol/l on day 
of study 
LOS: 3 days 
 
DV: PP BG 
 
IV: TIA-  
IV1: PRE: 
30 minutes 
prior to meal 
 
IV2: PRE:  
15 minutes 
prior to meal 
 
IV3: "0" 
Immediately 
before meal 
CGM- Sof-
Sensor 
Medtronic  
 
BS: q15 mins 
@ 1h PRP, q 10 
mins @ 2h PP, 
and q20 mins @ 
3 & 4 hour PP 
 
AUC  
Trapezoid 
method 
 
SPSS 17 for S = 
p < 0.005  
 
ANOVA 
 
Paired sample t-
test  
 
Fisher exact  
DV1 had S 
lower AUC 
vs. DV2 & 
DV3 - p 
<0.029 
 
DV1 had S 
lower GE 
vs. DV2 & 
DV3 - p < 
0.009 
LOE: II 
 
Strengths:  
Homogeneity of meals and 
compliance  
0% ATR  
 
Limitations:  
Small sample sized  
Funding by Novo Nordisk 
 
Confidence to Act:  
Yes, strong evidence, easily 
replicated, and can be generalized 
to population. 
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indices, HBM-health belief model, HE- hypoglycemic episodes,  HRQOL- health related quality of life, I-insulin, IC-inclusion criteria, ID-insulin dependent, IGC- intensive glucose control, II-insulin 
injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
 
EC:  
BG  < or > 3.5-
7.8 mmol/l on 
day of study 
 
Scaramuzza 
(2010) 
Timing of 
bolus in 
children with 
type 1 diabetes 
using 
continuous 
subcutaneous 
insulin 
infusion  
 
L: Italy  
 
F: NR  
 
C/B: No 
HBM Design: 
NRCT  
 
Purpose: 
To determine 
optimal timing of 
bolus injection in 
children with 
T1D.   
n = 30 
 
Demographics: 
Age range (6-20 
y/o) 
Mean age = 
15.2 
13 females 
17 males 
 
 
Setting:  
Hospital  
 
ATR: 0% 
 
IC: 
Diagnosed with 
T1D for 
average of 8 
years, BMI 
22.4, insulin 
requirement 
0.77 +/- 0.21 
LOS: 3 days 
 
DV: PP BG 
 
IV: TIA 
IV1: PRE: 
15 mins PRP 
 
IV2: 
START: 
immediately 
PRP 
 
IV3: POST: 
immediately 
PP 
 
 
 
M- FreeStyle 
Lite 
 
IP- Paradigm 
522/722 
 
I- Novorapid 
 
AUC 
 
 
 
 
 
 
 
 
 
 
 
ANOVA  
 
S = p < 0.05  
BG 60 mins 
PP:  
 DV1 vs. 
DV3 - p = 
0.044 
 
DV2 vs. 
DV3- p = 
0.024 
LOE: III 
 
Strengths:  
Low risk 
Used same short-acting analog 
and same meter; glucose meter 
calibrated daily  
Standardized meals  
Same range of preprandial BG 
(80-140) 
NCI 
0% ATR 
 
Limitations:  
Small sample 
No blinding and no 
randomization 
No discussion of exclusion 
criteria  
 
Confidence to Act:  
Yes, the study has no ATR, easy 
to replicate, and low risk.  
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injection, IPT-insulin pump therapy, IV-independent variable, KA- ketoacidosis, L-location, LBGI-low BG indices, LOE-level of evidence, LOS-length of study, LR-low risk, M-meter, MA-mean 
age, MC- macrovascular complications, MI- myocardial infarction, MIC- microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-
non-randomized control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, PBGP-point BG profile, PG-parallel 
group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized 
cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
 
Author Conceptual 
Framework 
Design/Purpose Sample/Setting Major 
Variables 
Measurement Data 
Analysis/Stats 
Used 
Study 
Findings 
Evidence/Strengths/Limitations
/Confidence to Act 
U/kg/d, and 
using insulin 
pump >= 6M 
 
EC: NR 
Schernthaner 
(2004) 
Preprandial vs. 
postprandial 
insulin lispro-
a comparative 
crossover trial 
in patients 
with type 1 
diabetes 
 
L: Austria  
 
F: Eli Lilly & 
Co  
 
C/B: Yes 
PT Design: 
RCO 
 
Purpose: 
To compare 
metabolic effects 
of preprandial vs 
postprandial 
injection of bolus 
insulin lispro. 
n = 31 
nPRE = 16 
nPOST = 15 
 
Demographics: 
Mean age = 31 
Mean BMI = 
24.3 +/- 
2.3kg/m2 
 
Setting:  
OP  
 
ATR: NR  
 
IC:  
ID, diagnosed 
before 40 y/ 
with T1D, II 3+ 
times/day, 
HbA1c <= 8%, 
BMI <35kg/m2, 
no 
advanced/rapidl
y progressing 
LOS: 6 
months  
 
DV: HbA1c 
& 
Fructosami
ne 
 
IV: TIA -  
IV1: PRE- 
immediately 
PRP  
 
IV2: POST- 
immediately 
to 30 
minutes PP 
 
High 
performance 
liquid 
chromatography 
for A1c  
 
Colorimetric 
test by reaction 
with nitroblue 
tetrazolium for 
fructosamine 
with coefficient 
of variation of 
2% 
 
Model 
appropriate for 
crossover design 
to test for 
carryover effects 
if any  
 
Analysis of 
variance  
 
8-point BG 
measurements  
 
Mean A1c 
in from 
baseline to 
final - DV1 
< DV2 - p = 
0.008 
 
Mean PP 
BG DV2 > 
DV1 - p = 
0.031 
 
 
LOE: II 
 
Strengths:  
Randomized  
Discussion of search criteria  
 
Limitations:  
No homegeneity of meals and 
compliance  
Small sample sized  
Funding by Eli Lilly & Co 
 
Confidence to Act:  
Yes, the study was well designed 
with reliable results. 
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cross over, RCT-randomized controlled trials, ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, T2D-type 2 
diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
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A-average, AA-average age, A1c-HbA1c, AE- adverse events, AR-age range, ATR-attrition rate, AUC-area under the curve, BG-blood glucose, 
BGC-blood glucose concentration, BGRI-blood glucose risk index, BNRPS-blinded non-randomized pilot study, BS- blood sample, C/B-
conflict/bias, CC-carb counting, CCID-carbohydrate counting for insulin dose, CD-celiac disease, CFB-change from baseline, CG-comparison 
group, CGC- conventional glucose control, CGM-continuous glucose monitoring, CO-crossover, CSII-continuous subcutaneous insulin 
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microvascular complications, MLM-mixed linear model, MO-matched observations, MVA-multivariable analysis, NRCT-non-randomized 
control trials, NS-non-significant, NR-not reported, OSNIT-one sided non-inferiority test, OP-outpatient, OWB-one way blinding, P-potential, 
PBGP-point BG profile, PG-parallel group, PM-post meal, PO- primary outcome, PP-postprandrial, PRP-preprandial, PRP II- preprandial 
insulin satisfaction, PS-pilot study, PT-physiologic theory, R-randomized, RCO-randomized cross over, RCT-randomized controlled trials, 
ROLT-randomized open-label trials, S-significant, SO- secondary outcome, SV-supervised, TIA-insulin administration, T1D-type 1 diabetes, 
T2D-type 2 diabetes, TDID-total daily insulin dose, STSQM-Diabetes treatment satisfaction questionnaire, Y/O-years old 
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Appendix I 
 
 
Demographic Table  
 
Gender  Male  Female   
 3 4  
Ethnicity  African American  Hispanic  Hispanic & Caucasian  
 3 3 1 
Age  8-12 13-17  
 2 5  
Age of Diagnosis  7-10 11-14 15-18 
 5 2  
 
 
Cost Analysis  
 
Materials  Cost 
Printing costs  5-10 
Pens (available in each exam room)  0 
Travel time & cost (gasoline)  6 hours ; $30 
Total  35  
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Appendix J  
 
 
6850 North Durango Drive, Suite #301, Las Vegas, Nevada 89149 
Phone: 702-641-8500 • Fax: 702-641-8502 • pedsendo@horizonviewmc.com 
Dear Parents of Horizon View Medical Center,  
 
 
My name is Ngoc Quyen Bui RN, and I am a Doctor of Nursing Practice at Arizona State University. I have been 
granted permission from Dr. Rola Saad and Nurse Practitioner Trisha Briones APRN, CPNP to complete a practice 
change project for Horizon View Medical Center. I am working under the direction of Diana Jacobson PhD, RN, 
PPCNP-BC, FAANP at Arizona State University College of Nursing and Health Innovation. 
The purpose of this Doctor of Nursing Practice (DNP) project is to educate you and your child about giving your 
child’s insulin prior to the planned meal instead of giving the insulin after your child completes his or her meal. As a 
part of this DNP project, we would like to have you and your child fill out two short surveys, once at the beginning 
of the project and once again three months later, that ask questions about you, your child’s health, your child’s 
diabetes management and your knowledge about diabetes. Your child’s blood glucose, hemoglobin A1c, and weekly 
blood glucose reports will be obtained from the electronic medical records at Horizon View Medical Center as part 
of this project. Your part in the DNP project will take the length of a routine office clinic visit (15-30 minutes) on 
two different days and this includes the time for diabetes management education and the completion of the surveys. 
The inclusion criteria for parents and children in this project include a diagnosis of type 1 diabetes for at least 3 
years for the child, stability of your child’s health on his or her current health plan, the child’s age between 6-18 
years old, English speaking for both the child and parent, and the child with a HbA1c greater than 8% since last 
office visit. 
A four digit identification (ID) number using the last four digits of your telephone number will be created at the 
initial visit. The purpose of this ID number is to protect you and your child’s privacy.  
Please let the front office staff or one of the providers know if you are interested in participating and Ms. Bui will 
give you more information.  
Sincerely,  
Ngoc Quyen Bui RN 
 
 
 
 
 
 
 
 
ASU IRB IRB # STUDY00003484 | Approval Period 1/3/2016 – 1/2/2017 
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Appendix K  
 
How to create an identification (ID) number  
• Choose a home, work, or cell phone that you and your child can easily remember.  
• Use the last 4 digits of this phone number to create your personal ID for this research study.  
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Appendix L 
 
Teaching Handout 
Glycemic goals:  
 HgA1c Before Meals BG Bedtime/Overnight BG  
6-12 years ≤ 7.5% 90-180 mg/dL 100-180 mg/dL 
13-19 years ≤ 7% 90-130 mg/dL 90-150 mg/dL  
Recommended carbohydrates per meal:  
 5-12 years 13-19 years 
Male 45-60g 60-75g 
Female 45-60g 45-75g 
For hypoglycemic episodes, fast acting snacks need to provide 15-30g of carbohydrate 
• 3-5 pieces of hard candy 
• 4-6 ounces of regular soda or orange juice 
• 2 tablespoons of raisins 
• 8 ounces of nonfat or low fat milk 
Schedule for Insulin Administration:  
If blood glucose level is:  Give the insulin at this time before eating:  
< 200 mg/dL 10 minutes prior to meal  
200-300 mg/dL 20 minutes prior to meal  
> 300 mg/dL 30 minutes prior to meal 
If unable to predict carb intake  Correct the blood sugar prior to eating using the chart 
above  
Contact information:  
• In case of emergency:  call 9-1-1 
• For questions or concerns: call 702-641-8500 or email diabetes@horizonviewmc.com 
References:  
1. Centers for Disease Control and Prevention http://www.cdc.gov/features/diabetesinschool/ 
2. International Diabetes Federation https://www.idf.org/sites/default/files/attachments/HI62553-Carbohydrate-Counting-for-
Children.pdf 
3. American Diabetes Association http://www.diabetes.org/food-and-fitness/food/what-can-i-eat/understanding-
carbohydrates/carbohydrate-counting.html 
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Appendix M 
 
 
First visit Child Survey 
 
ID number        Date: 
Age:          What was your last HbA1c: ______ 
Gender: Boy or Girl           
Ethnicity:  
Hispanic/Latino Asian  Caucasian Black  Pacific Islander  Native American 
Other  
1. When do you give yourself insulin shots? 
 
Before meals  During meals  After meals  
 
2. Are you comfortable giving yourself insulin shots? 
 
0  1 2 
No Maybe Yes 
 
3. Do you know your current insulin to carbohydrate ratio (I:C)?  If yes, what is it? 
Yes  No    I don’t know 
 
4. Put a check next to all the snacks that give you at least 15g of carbohydrates in case your blood sugar 
is less than 70 mg/dL?  
⃝  3-5 pieces of hard candy 
⃝  4-6 ounces of regular soda or orange juice 
⃝  2 tablespoons of raisins 
⃝  8 ounces of nonfat or low fat milk 
5. Where on your body can you give insulin? Put a check mark next to all that are true. 
⃝  Stomach 
⃝  Back of your arms 
⃝  Thighs 
6. How many days go by before you change where you give insulin? 
⃝  I never change where I inject insulin. 
⃝  1 day 
⃝  2 days 
⃝  3 days 
⃝  4 days 
⃝  5 days 
 
Pre-assessment survey for Parents 
 
ID number        Date: 
Child’s current age:        Current HbA1c:  
Child’s Age at diagnosis:   
Please circle Parent Ethnicity:  
Hispanic/Latino  Asian  Caucasian Black  Pacific Islander   
Native American Other 
 
1. When do you or your child currently administer short-acting insulin? 
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Before meals  During meals  After meals  
 
2. Do you think administering insulin before meals would improve your child’s blood glucose 
control?  
Yes  No  I don’t know  
3. How comfortable are you with insulin administration? 
1 2 3 4 5 
Uncomfortable at 
all times 
A little 
uncomfortable 
most of the time  
Somewhat 
comfortable 
Most of the time I 
am comfortable 
Very comfortable 
all the time 
 
4. What is your child’s current Insulin to carbohydrate ratio (I:C)? 
 
5. Fill in the blank:  
 
If your child’s blood glucose level is:  Give the insulin at this time before eating:  
< 200 mg/dL ____      minutes prior to meal  
200-300 mg/dL ____     minutes prior to meal  
> 300 mg/dL ____     minutes prior to meal 
If unable to predict carbohydrate intake  Correct the blood sugar prior / after (circle one) to 
eating using the chart above  
 
6. What area does your child use for insulin administration?  
 
7. How often does your child rotate injection sites? 
8.  
 
9. What do you do if your child is sick and does not want to eat? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix N 
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Second Visit Child Survey 
 
ID number        Date: 
Age:          What was your last HbA1c: ______ 
Gender: Boy or Girl         
1. When do you give yourself insulin shots? 
 
Before meals  During meals  After meals  
 
 
2. Are you comfortable giving yourself insulin shots? 
 
0  1 2 
No Maybe Yes 
 
 
3. Do you know your current insulin to carbohydrate ratio (I:C)?  If yes, what is it? 
Yes  No    I don’t know 
 
 
4. Put a check mark next to all the snacks that give you at least 15g of carbohydrates in case your 
blood sugar is less than70 mg/dL?  
⃝  3-5 pieces of hard candy 
⃝  4-6 ounces of regular soda or orange juice 
⃝  2 tablespoons of raisins 
⃝  8 ounces of nonfat or low fat milk 
5. Where on your body can you give insulin? Put a check mark next to all answers that are true. 
⃝  Stomach 
⃝  Back of your arms 
⃝  Thighs 
5. How many days go by before you change where you give insulin? 
⃝  I never change where I inject insulin. 
⃝  1 day 
⃝  2 days 
⃝  3 days 
⃝  4 days 
⃝  5 day 
 
 
 
 
Post-assessment survey for Parent 
 
ID number:         Date: 
1. Did you notice a change in blood glucose control with pre-meal administration? If yes or sometimes, what did 
changes did you notice? 
Yes   No  Sometimes 
________________________________________________________________________________ 
2. In the last week, how many times did your child have symptoms of hypoglycemia (IE. dizziness, clamminess, 
confusion, seizures)? 
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0 days per week 1-3 days per week 4-5 days per week 6-7 days per week  
3. How comfortable are you with administering insulin for your child? 
1 2 3 4 5 
Uncomfortable at all 
times 
A little uncomfortable 
most of the time  
Somewhat comfortable Most of the time I am 
comfortable 
Very comfortable all 
the time 
 
4. Are you satisfied with pre-meal administration of insulin for your child? 
1 2 3 4 5 
Extremely dissatisfied Somewhat dissatisfied Neither satisfied or 
dissatisfied 
Satisfied Extremely Satisfied  
 
5. Was your child hospitalized, injured, or ill in the last 3 months? Describe the changes, if any, that occurred 
with your child’s blood sugar control during these times. Please explain below.  
 
6. What do you do if your child is sick and does not want to eat? 
 
7. What area does your child use for insulin administration? 
 
8. How often does your child rotate injection sites? 
 
9. Fill in the blank:  
 
If your child’s blood glucose level is:  Give the insulin at this time before eating:  
< 200 mg/dL ____      minutes prior to meal  
200-300 mg/dL ____     minutes prior to meal  
> 300 mg/dL ____     minutes prior to meal 
If unable to predict carb intake  Correct the blood sugar prior / after (circle one) to eating using the 
chart above  
 
10. Please write any other comments or concerns about pre-meal insulin administration here:  
 
 
 
